Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis

<p class="MsoNormal">Featuring an interview from Dr John Strickler, including the following topics:</p> <ul> <li>Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00)</li> <li>Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09)</li> <li>Tumor-informed MRD assays under clinical development (20:36)</li> <li>Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19)</li> <li>Case: A man in his late 50s with resected Stage IIA colon cancer (30:06)</li> <li>Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57)</li> <li>MRD as a future clinical tria...